Core Viewpoint - SS Innovations International, Inc. has submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system, aiming to enhance accessibility and affordability of robotic surgery in the U.S. market [1][2] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery accessible to a broader global population [5] - The company is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] Product Details - The SSi Mantra surgical robotic system features a modular design with 3 to 5 robotic arms, an ergonomic command center, and advanced imaging capabilities [6] - It has been clinically validated in India for over 100 different types of surgical procedures [6] Regulatory Progress - The FDA aims to complete reviews of 510(k) submissions within 90 days, although actual approval times may vary [3] - The company is also pursuing CE marking certification in the European Union, expected in the first half of 2026 [3] Market Presence - As of November 30, 2025, the SSi Mantra has a cumulative installed base of 138 systems across eight countries, with 137 hospitals utilizing the system [4] - Over 7,300 surgical procedures have been performed using the SSi Mantra, including 88 telesurgeries and 390 cardiac procedures [4]

Core Insights - The recent market correction has created buying opportunities for investors in high-growth companies that are addressing real-world problems, with many stocks trading at 30-day lows despite strong operational progress [1][2]. Group 1: Symbotic (SYM) - Symbotic develops AI-enabled robotic systems for automating high-volume warehouses, reporting Q3 2025 revenue of $592 million, a 26% year-over-year increase, and adjusted EBITDA rising to $45 million from $3 million [3][5]. - The company has a significant backlog of approximately $22.4 billion, primarily from long-term contracts with Walmart and GreenBox, providing multiyear revenue visibility [5][6]. - Despite a 14% decline in shares over the past 30 days, the company is positioned for growth with a substantial contracted workload ahead [6]. Group 2: AST SpaceMobile (ASTS) - AST SpaceMobile aims to create the first space-based cellular broadband network compatible with standard smartphones, achieving Q3 2025 revenue of $14.7 million, up from $1.1 million a year ago, driven by government contracts [7][9]. - The company has over $1 billion in contracted revenue commitments and has signed agreements with more than 50 mobile network operators, serving nearly 3 billion subscribers [9][10]. - Execution and launch timelines are critical factors, with recent revenue misses contributing to stock volatility, but the current weakness offers a favorable entry point for investors [10]. Group 3: SS Innovations International (SSII) - SS Innovations has installed over 100 SSi Mantra surgical robotic systems and completed over 5,000 procedures, indicating a transition from concept to scale [11][13]. - The company plans to file a 510(k) premarket notification in Q4 2025 for multiple surgical indications, which could expedite FDA clearance [13][14]. - This small-cap stock has shown less volatility compared to others, with only a 5% decline over the past 30 days as investors await regulatory updates [15].

Core Insights - SS Innovations has successfully completed the first telesurgery using its SSi Mantra Tele Surgeon Console (TSC), marking a historic milestone in robotic telesurgery [1][4][5] Group 1: Product Overview - The SSi Mantra Tele Surgeon Console is a compact, self-contained, chair-based system designed for telesurgery, allowing operations from various locations, including physician offices [2][4] - The TSC features 3D visualization, magnetic sensor controls, and a smaller footprint compared to traditional operating room setups, enhancing flexibility for surgical experts [7][9] Group 2: Surgical Achievement - Dr. Sudhir Srivastava performed a robotic-assisted coronary artery bypass surgery remotely from New Delhi on a patient located 185 miles away in Jaipur, demonstrating the TSC's capability to extend surgical expertise globally [3][5] Group 3: Company Vision and Future Plans - SS Innovations aims to make robotic surgery affordable and accessible to a broader global population, with plans to expand its presence and technological offerings [8] - The company has refined the TSC since its initial showcase at the Society of Robotic Surgery Meeting in June 2024, indicating ongoing innovation and development [5]

Core Insights - SS Innovations International, Inc. has successfully completed its first telesurgery using the SSi Mantra Tele Surgeon Console (TSC), demonstrating the console's capability to facilitate surgeries from various locations, including physician offices [1][2][3] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [4] - The company is headquartered in India and plans to expand its global presence with user-friendly and cost-effective surgical robotic solutions [4] Product Details - The SSi Mantra Tele Surgeon Console is a compact, self-contained chair-based system that allows for telesurgeries without the need for a full operating room [1][3] - The TSC features inbuilt electronics, lightweight glasses, a magnified 3D view, and magnetic sensor-based controls, making it suitable for remote surgical procedures [3] - The SSi Mantra surgical robotic system includes modular robotic arms, a 3D 4K monitor, and supports over 40 types of robotic endo-surgical instruments for various specialties, including cardiac surgery [5]

Revenue Growth - Revenue increased 192.5% year over year to $12.8 million from $4.4 million in Q3 2024[5] - Total revenue for the first nine months of 2025 increased 123.0% to $28.0 million from $12.5 million in the first nine months of 2024[5] - Total revenue for Q3 2025 reached $12,829,349, a significant increase of 192% compared to $4,386,516 in Q3 2024[20] - For the nine months ended September 30, 2025, total revenue was $27,950,264, an increase of 123% from $12,533,335 in the same period of 2024[21] Gross Profit and Margin - Gross profit rose 166.0% to $6.2 million from $2.3 million in Q3 2024[5] - Gross profit for Q3 2025 was $6,164,936, compared to $2,317,407 in Q3 2024, reflecting a gross margin improvement[20] System Installations and Surgeries - SSi Mantra surgical robotic system installations totaled 27, up 350.0% from 6 installations in Q3 2024[5] - SSi Mantra installations for the first nine months of 2025 totaled 63, up 152.0% from 25 installations in the first nine months of 2024[10] - Cumulative surgeries reached 6,057, including 56 telesurgeries and 319 cardiac procedures[5] Net Loss and Financial Performance - Net loss of $3.7 million, or $(0.02) per diluted share, compared to a net loss of $3.2 million, or $(0.02) per diluted share, in Q3 2024[5] - The net loss for Q3 2025 was $3,717,964, compared to a net loss of $3,245,483 in Q3 2024, indicating a worsening of financial performance despite revenue growth[20] Cash and Liquidity - Cash and cash equivalents totaled $5.7 million, excluding restricted cash[5] - Cash and cash equivalents at the end of Q3 2025 were $12,039,247, up from $6,152,262 at the end of Q3 2024, showing improved liquidity[23] Operating and Research Expenses - Operating expenses for the nine months ended September 30, 2025, totaled $20,626,239, slightly down from $21,620,651 in the same period of 2024[21] - Research and development expenses for the nine months ended September 30, 2025, were $2,295,014, an increase from $1,729,834 in the same period of 2024[21] Foreign Currency Impact - The company reported a foreign currency translation loss of $480,822 in Q3 2025, compared to a loss of $59,087 in Q3 2024[20] Future Plans - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025[6] - The company aims for European Union CE marking certification in the first half of 2026[6] Share Dilution - The weighted average diluted shares increased to 202,856,501 in Q3 2025 from 181,885,269 in Q3 2024, reflecting dilution from equity financing[20]

Financial Performance - Total revenue for the three months ended September 30, 2025, was $12,829,349, a significant increase from $4,386,516 for the same period in 2024, representing a growth of approximately 192%[202]. - Gross profit for the three months ended September 30, 2025, was $6,164,936, compared to $2,317,407 in the same period of 2024, reflecting an increase in gross profit margin due to lower raw material prices[203]. - For the nine months ended September 30, 2025, total revenue was $27,950,264, compared to $12,533,335 for the same period in 2024, marking an increase of approximately 123%[212]. - The net loss for the three months ended September 30, 2025, was $3,717,964, compared to a net loss of $3,245,483 for the same period in 2024, despite an increase in gross profit[211]. - The Company reported a net loss of $17,227,806 for the nine months ended September 30, 2024, with non-cash adjustments of $13,528,234[232]. Market Activity - The company sold 28 surgical robotic systems in the three months ended September 30, 2025, and 55 systems in the nine months ended September 30, 2025, indicating a growing market presence[197]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $786,319, up from $442,839 in the same period of 2024, reflecting ongoing investment in product enhancements[204]. - Selling, general and administrative expenses increased to $4,821,552 for the three months ended September 30, 2025, compared to $2,508,479 in the same period of 2024, primarily due to higher legal and underwriting fees[207]. Assets and Cash Flow - Total assets as of September 30, 2025, were $69,577,027, up from $42,385,213 as of December 31, 2024, indicating strong growth in the company's financial position[200]. - Cash at the end of the year on September 30, 2025, was $12,039,247, compared to $6,152,262 at the end of the previous year[230]. - In the nine months ended September 30, 2025, the net cash used in operating activities was $17,023,417, resulting from a net loss of $9,656,008[230]. - The Company had a net cash used in investing activities of $1,944,527 for the purchase of property and equipment during the nine months ended September 30, 2025[234]. Financing Activities - The Company raised $24,793,391 from financing activities during the nine months ended September 30, 2025, primarily from the issuance of convertible notes[235]. - The Company sold $2,450,000 in principal amount of 7% Convertible One-Year Promissory Notes, with a conversion price of $4.45 per share[225]. - As of September 30, 2025, all $30,000,000 in principal amount of One-Year Notes were converted into 21,858,368 shares of common stock at a conversion price of $1.38 per share[228]. - The net cash provided by financing activities in the nine months ended September 30, 2024, was $6,014,946, including proceeds from convertible notes and promissory notes[236]. - The Company raised $2,000,000 from Sushruta through the issuance of two One-Year 7% Promissory Notes in April 2024[226]. Taxation and Funding Concerns - The company incurred an income tax expense of $1,847,059 for the three months ended September 30, 2025, due to the recognition of taxable profits in its Indian operations for the first time[210]. - The Company does not have any committed sources of funding, raising substantial doubt about its ability to continue as a going concern[229]. - The Company plans to raise additional capital through private or public offerings to support its expansion and R&D efforts, highlighting the need for ongoing funding[201].

Core Insights - SS Innovations International, Inc. reported a significant revenue increase of 192.5% year-over-year, reaching $12.8 million in Q3 2025, primarily driven by higher sales of the SSi Mantra 3 surgical robotic system [1][6][11] Financial Performance - Q3 2025 revenue rose to $12.8 million from $4.4 million in Q3 2024, with a gross profit increase of 166.0% to $6.2 million [6][11] - Gross margin for Q3 2025 was 48.1%, down from 52.8% in Q3 2024 [6] - The net loss for Q3 2025 was $3.7 million, consistent with the net loss of $3.2 million in Q3 2024 [6][11] - For the first nine months of 2025, total revenue increased by 123.0% to $28.0 million compared to $12.5 million in the same period of 2024 [6][8] - Cumulative surgeries performed using the SSi Mantra reached 6,057, including 56 telesurgeries and 319 cardiac procedures [6][12] Business Highlights - The number of SSi Mantra installations in Q3 2025 totaled 27, a 350.0% increase from 6 installations in Q3 2024 [6][11] - The cumulative installed base of SSi Mantra systems reached 127 across seven countries [6][11] - The company has received regulatory approval for the SSi Mantra in seven countries and is preparing to enter the U.S. and European Union markets [4][12] Upcoming Developments - The company plans to submit a 510(k) premarket notification to the FDA in Q4 2025 and aims for CE marking certification in the EU in the first half of 2026 [4][12] - SS Innovations is scheduled to participate in investor conferences in November 2025, providing opportunities for management to engage with investors [9][10]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to make robotic surgery affordable and accessible globally [2][5] - The company will participate in upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference [3][4] Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with cost-effective surgical robotic solutions [5] - The company's product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various surgical procedures, including robotic cardiac surgery [5] Product Performance - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals having installed the system [6] - Over 6,000 surgical procedures have been performed using the SSi Mantra, including 60 telesurgeries and 310 cardiac procedures [6] Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system featuring advanced technology such as 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time image display [7] - It utilizes over 40 different types of robotic endo-surgical instruments and has been clinically validated in India for more than 100 different types of surgical procedures [8]

Core Insights - SS Innovations International, Inc. is focused on developing innovative surgical robotic technologies to enhance the accessibility and affordability of robotic surgery globally [4][5]. Company Overview - SS Innovations is headquartered in India and aims to expand its global presence with its advanced and cost-effective surgical robotic solutions [4]. - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which cater to various surgical procedures, including robotic cardiac surgery [4]. Recent Developments - As of September 30, 2025, the SSi Mantra has a cumulative installed base of 125 systems across six countries, with 119 hospitals utilizing the system [5]. - Over 6,000 surgical procedures have been performed using the SSi Mantra, which includes 60 telesurgeries and 310 cardiac procedures [5]. Upcoming Events - Dr. Sudhir Srivastava and Dr. Vishwa Srivastava will participate in the UBS Global Healthcare Conference on November 11, 2025, and the Stifel 2025 Healthcare Conference on November 12, 2025 [2][3]. - The Stifel conference will feature a group presentation at 4:40 p.m. Eastern Time, with a live webcast available on the company’s website [3]. Product Features - The SSi Mantra is a modular, multi-arm surgical robotic system equipped with advanced technology features, including 3 to 5 robotic arms, a 3D 4K monitor, and a virtual real-time imaging capability [6]. - It supports over 40 different types of robotic endo-surgical instruments, validated in more than 100 types of surgical procedures in India [6].

Core Insights - SS Innovations International, Inc. has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital, marking a significant milestone in its regulatory process [1][2] - The company plans to submit a 510(k) premarket notification to the FDA in the fourth quarter of 2025, aiming for potential market clearance in the first half of 2026 [1][3] - The SSi Mantra has a cumulative installed base of 125 systems across six countries, with over 6,000 surgical procedures performed to date [4] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies to make robotic surgery more affordable and accessible globally [5] - The SSi Mantra system features a modular design with advanced technology, including multiple robotic arms and a 3D 4K monitor, supporting various surgical specialties [6] Regulatory Pathway - The company has shifted from a De Novo request to a 510(k) regulatory pathway, which is expected to provide speed and cost advantages in the approval process [4] - RQM+, a MedTech-focused CRO, has been engaged to assist with the 510(k) submission [2]